CD8A and hepatocellular carcinoma: Similarly, we used an anti-IFN-γ antibody to inhibit the function of IFN-γ+CD8+ T cells in vivo (Figure 4g) and found that the anti-tumor effect of sorafenib promoted by Efm against HCC was also abrogated (Figure 4h).